Targeting Candida spp. to develop antifungal agents

Drug Discov Today. 2018 Apr;23(4):802-814. doi: 10.1016/j.drudis.2018.01.003. Epub 2018 Jan 19.

Abstract

Invasive fungal infections are a complex challenge throughout the world because of their high incidence, mainly in critically ill patients, and high mortality rates. The antifungal agents currently available are limited; thus, there is a need for the rapid development of new drugs. In silico methods are a modern strategy to explore interactions between new compounds and specific fungal targets, but they depend on precise genetic information. Here, we discuss the main Candida spp. target genes, including information about null mutants, virulence, cytolocalization, co-regulatory genes, and compounds that are related to protein expression. These data will provide a basis for the future in silico development of antifungal drugs.

Publication types

  • Review

MeSH terms

  • Animals
  • Antifungal Agents / pharmacology*
  • Candida / drug effects*
  • Candida / genetics*
  • Critical Illness
  • Humans
  • Mycoses / drug therapy
  • Mycoses / genetics*
  • Virulence / genetics

Substances

  • Antifungal Agents